🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "significant breakthrough" in the battle against increasingly resistant strains of the pathogen, according to researchers.

A Worldwide Public Health Issue

Gonorrhoea infections are escalating worldwide, with estimates suggesting in excess of 82 million new cases each year. Notably increased rates are reported in the African continent and countries within the WHO's designated area, which includes China and Mongolia to New Zealand. In England, cases have hit a record high, while figures across Europe in 2023 were significantly elevated compared to figures for 2014.

“The approval of fresh medications for gonorrhoea is an significant and necessary step in the context of growing infection rates, the spread of superbugs and the extremely scarce treatment choices currently available.”

Medical experts are increasingly worried about the increase in treatment-resistant strains. The WHO has designated it as a "high-priority threat". Recent surveillance showed that the effectiveness of key first-line drugs like cefixime and ceftriaxone jumped significantly between 2022 and 2024.

Two New Drugs Gain Authorization

Zoliflodacin, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This disease can lead to major issues, including infertility. Experts anticipate that targeted use of this new drug will help hinder the spread of drug resistance.

Gepotidacin, developed by the drugmaker GlaxoSmithKline, was also approved in the same week. This drug, which is also used to treat UTIs, was proven in research to be able to combat antibiotic-resistant forms of the gonorrhoea bacteria.

A Novel Partnership

This new treatment stemmed from a unique collaborative effort for antibiotic development. The charitable organization GARDP collaborated with the pharmaceutical company Innoviva to see it through.

“This authorization marks a major breakthrough in the therapy of highly resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Research Study Outcomes and Worldwide Availability

According to data released by a major medical journal, zoliflodacin cured the vast majority of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which involves a dual-drug approach. The trial included nearly 1,000 patients from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, GARDP has the rights to register and commercialise the drug in numerous low-income and middle-income countries.

Doctors directly involved have expressed positive views. Access to a one-pill regimen such as this is described as a "critical tool" for public health efforts. This is deemed essential to reduce the burden of the disease for patients and to halt the transmission of untreatable gonorrhoea around the world.